These are the 3 worst performers on the S&P/ASX 200 over the last 12 months

Despite recent weakness on the local share market, during the last 12 months the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has managed to carve out a gain of just under 7%.

Unfortunately, not all shares have been able to follow the benchmark index higher. In fact, the three shares listed below have been the worst performers on the market. Is it time to snap them up now?

The Mayne Pharma Group Ltd (ASX: MYX) share price has fallen 67% since this time last year. Price-fixing allegations and pricing pressures in the lucrative U.S. generic drugs market have weighed heavily on the pharmaceutical company’s shares. Whilst I think that Mayne Pharma could be dirt cheap if these headwinds dissipate, until that happens I would suggest investors hold off an investment.

The Sirtex Medical Limited (ASX: SRX) share price has plunged 55% in the last 12 months. The regenerative medicine company’s shares have been free-falling since its two most recent clinical trials, SARAH and FOXFIRE, showed no improvement in overall survival rates versus the current standards of care. Furthermore, the company failed to deliver the explosive dose sales growth that many in the market had expected. While Sirtex may be about fair value right now, I think there are investments that offer a more compelling risk/reward elsewhere on the market.

The Vocus Group Ltd (ASX: VOC) share price has tumbled 66% since this time last year. While the telco industry as a whole has come under significant pressure this year, investors have been heading to the Vocus exits due largely to its underwhelming performance, weaker NBN margins, boardroom spats, and a possible class action. Unfortunately, I can’t see any real catalyst to take its shares higher in the near-term, so would expect its shares to trade sideways or even lower for the foreseeable future. Unless, of course, there is a real uptick in its performance.

If you want to avoid declines like those above, a good place to start would be selling these toxic shares.

Do You Own These 3 Toxic ASX Stocks?

Alert For ASX Investors: Warning, Remove These 3 Stocks From Your Portfolio Now.

This breaking research reveals why these 3 popular stocks could be in for a big fall.

Simply click here to access your FREE report, “3 Toxic Aussie Stocks to Avoid at All Costs” today!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Vocus Communications Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.